ReviewClinical rheumatology2018
Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.
Review in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- The immunometabolic tipping point: forecasting the systemic shift from psoriasis to psoriatic arthritis.Frontiers in immunology · 2026Review
- Article
- Understanding the interplay between psoriatic arthritis and gout: "Psout".Rheumatology international · 2024Review
- Association Between Non-HDL to HDL Cholesterol Ratio (NHHR) and Psoriasis in Adults: A Cross-Sectional Study Using 2009-2014 Data.Clinical, cosmetic and investigational dermatology · 2024Article
- A Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome.Clinical, cosmetic and investigational dermatology · 2024Article
- The relationship between blood lipid and risk of psoriasis: univariable and multivariable Mendelian randomization analysis.Frontiers in immunology · 2023Article
- JAK Inhibitors in Psoriatic Disease.Clinical, cosmetic and investigational dermatology · 2023Review
- Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- Metabolic Syndrome and Its Components in Psoriatic Arthritis.Open access rheumatology : research and reviews · 2022Review
- Psoriatic arthritis in Africa.Clinical rheumatology · 2021Review
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.Rheumatology international · 2021Review
- Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study.Rheumatology international · 2020Observational
- The place of omega-3 and omega-6 acids in supplementary treatment of inflammatory joint diseases.Reumatologia · 2020Review
- Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.Journal of experimental pharmacology · 2020Review
- Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.Drugs & aging · 2019Review
- Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis".Clinical rheumatology · 2019Article
- Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment.Clinical rheumatology · 2019Review
- Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis.Clinical rheumatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the prevalence of MetS and its components and the level of serum uric acid in patients with PsA and in those with PsA sine psoriasis. A secondary aim of the study was to investigate on correlations of MetS in all study population. Consecutive PsA patients underwent assessment of disease activity and metabolic parameters. Blood samples were collected after 12 h of overnight fasting and analyzed for glucose, lipid profile, serum uric acid, and acute-phase reactants. The NCEP-ACT III criteria were used to identify subjects with MetS. Forty-two patients (52.5%) were classified as having PsA with clinically evident psoriasis (group 1) and 38 (47.5%) as having PsA sine psoriasis (group 2). Group 1, when compared to group 2, showed a significant increase for the frequency of MetS (p = 0.006) and for mean values of diastolic blood pressure (p = 0.0116) and of serum uric acid (p = 0.04). We then aimed at defining determinants of MetS in the entire study population. In the multivariate analysis, three variables reached statistical significance: presence of psoriasis (OR 0.14; p = 0.01), increase of one unit of BMI (OR 1.26; p = 0.001), and smoking habit (OR 5.93; p = 0.02). In our study, the occurrence of MetS and mean levels of serum uric acid were higher in PsA patients with clinical evident psoriasis compared to sine psoriasis PsA. The results also show the potential role of BMI, psoriasis, and smoking as important determinants in the development of MetS in PsA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.